*IN THE CLAIMS*

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Complete Listing of Claims**:

1. (Currently Amended) A method of suspending, preventing or delaying ~~the~~ onset of type 1 diabetes in a subject ~~that has undergone IAA seroconversion~~, the method comprising administering to the subject a pharmaceutically acceptable composition comprising a fusion protein, wherein the fusion protein comprises at least one immunoglobulin having a variable region composed of at least one CDR region, the at least one immunoglobulin having at least one protein fragment or peptide inserted within the variable region; wherein (a) the protein fragment or peptide is selected from the group consisting of a protein fragment or peptide derived from INS, a protein fragment or peptide derived from GAD, ~~an insulin protein, a peptide derived from insulin,~~ a diabetogenic epitope, and a T cell receptor engaging determinant, or fragments of the foregoing; and (b) ~~wherein~~ the composition is administered to the subject in one or more dosage administrations.

2. (Original) The method of claim 1, wherein the immunoglobulin is human or humanized.

3. (Currently amended) The method of claim 1, wherein the subject is a human subject that has undergone IAA seroconversion.

4. (Currently amended) The method of claim 1, wherein ~~the~~ administration of the composition to the subject results in down regulation of an autoreactive T cell.

5. (Currently amended) The method of claim 1, wherein [[a]] the at least one protein fragment or peptide is inserted within a ~~variable region~~ CDR region of the at least one immunoglobulin.

6. (Currently amended) The method of claim 5, wherein the at least one CDR region ~~variable region of the immunoglobulin~~ comprises a one or more of a CDR1, a CDR2, or a CDR3 region.

7. (Currently amended) The method of claim 5, wherein administration of the composition to the subject results in substantially reduced activation of an autoreactive T cell specific for the at least one protein fragment or peptide ~~is substantially reduced or prevented~~.

8. (Withdrawn – currently amended) The method of claim 1, wherein the at least one protein fragment or peptide is derived from INS ~~comprises INSß~~.

9. (Withdrawn – currently amended) The method of claim 8, wherein the INS comprises soluble INSß.

10. (Withdrawn) The method of claim 9, wherein the soluble INSß is capable of binding to at least one Fc receptor.

11. (Withdrawn) The method of claim 10, wherein the Fc receptor is a Fcγ receptor.

12. (Withdrawn – currently amended) The method of claim 10, wherein the composition is capable of being endocytosed by antigen presenting cells.

13. (Currently amended) The method of claim 1, wherein the at least one protein fragment or peptide is derived from ~~GAD comprises GAD 1, GAD2, or~~ GAD65.

14. (Cancelled)

15. (Currently Amended) The method of claim 13, wherein the subject is GAD positive.

16. (Currently amended) The method of claim 1, wherein the subject has not developed hyperglycemia at initiation of the administering step.

17. (Currently amended) The method of claim 1, wherein the subject expresses a type 1 diabetes predisposition marker at initiation of the administering step.

18. (Currently amended) The method of claim 1, wherein upon administration of the composition to the subject, the subject undergoes a dose dependent suspension, prevention, or delay in ~~the~~ onset of type 1 diabetes.

19. (Currently amended) The method of claim 1, wherein ~~the~~ administration of a first dosage of the composition occurs before the subject has developed type-1 diabetes ~~progresses to an irreversible stage~~.

20. (Withdrawn) A composition for suppressing the onset of type 1 diabetes in a subject that has undergone IAA seroconversion, the composition comprises: a pharmaceutically acceptable composition comprising at least one immunoglobulin selected from the group consisting of INS, GAD, an insulin protein, a peptide derived from insulin, a diabetogenic epitope, and a T cell receptor engaging determinant.

21. (New) The method of claim 20 wherein the fusion protein is in soluble form.

22. (New) The method of claim 2 wherein the immunoglobulin is selected from the group consisting of IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgGA, IgA1, IgA2, IgGE, IgD, IgE, or IgM.

23. (New) The method of claim 5 wherein the at least one protein fragment or peptide is inserted in within the CDR3 region of the immunoglobulin.

24. (New) The method of claim 23 wherein the at least one protein fragment or peptide is inserted in within the CDR3 region of the immunoglobulin in place of a D segment.

25. (New) The method of claim 13 wherein the at least one protein fragment or peptide derived from GAD65 comprises amino acid residues 524-543 of GAD65.

26. (New) The method of claim 13 wherein the at least one protein fragment or peptide derived from GAD65 comprises amino acid residues 206-220 of GAD65.